Journal: bioRxiv

Article Title: Tumor Cell Death Drives Tumor-Promoting IL-6⁺ iCAF formation via P2X7-activation

doi: 10.64898/2026.03.18.712671

Figure Lengend Snippet: A) RNA-seq analysis of Control- or Gem-SU treated mPSCs. Heatmaps show differentially expressed genes related to activation of purinergic signaling. Color codes indicate Z-scores of each condition (n=3 mice per group). B) Graph shows the quantification of the mean fluorescence intensity of IL-6 stainings described in ( pooled data of 3 biological replicates). C ) Graph shows the quantification of the mean fluorescence intensity of IL-6 stainings described in (pooled data of 3 biological replicates). D ) Immunoblots of human PSC cells treated for 15 min with supernatants of vehicle (Control-SU) or doxorubicin treated (Dox-SU) MIA PaCa-2 cells. Where indicated the medium was supplemented with A438079 (n = 3 biological replicates). E) IL-6 immunostaining of hPSCs treated with Control- or Dox-SU in the absence or presence of PPADS or A430879 (scale bar = 100 µm, n= 3 biological replicates). Graph shows the quantification of the IL-6-immunofluorescence. F) RT–qPCR analysis of the indicated genes in mPSCs treated for 24h with Control-SU or Gem-SU in the absence or presence of the P2X7-inhibtitor A430879 (n = 2 biological replicates). All data are mean ± s.d. and were analyzed by one-way ANOVA with Tukey’s multiple comparison test (*p≤0.05; **p≤0.01; ***p≤0.0005; **** p≤0.0001; ns = not significant).

Article Snippet: Where indicated ( and ) P2X7-activation of PSCs was blocked by supplementing tumor cell supernatants with 40 μM A438079 (Santa Cruz Biotechnology, SC-203788B).

Techniques: RNA Sequencing, Control, Activation Assay, Fluorescence, Western Blot, Immunostaining, Immunofluorescence, Quantitative RT-PCR, Comparison

Journal: bioRxiv

Article Title: Tumor Cell Death Drives Tumor-Promoting IL-6⁺ iCAF formation via P2X7-activation

doi: 10.64898/2026.03.18.712671

Figure Lengend Snippet: A) RNA-seq analysis of Control- or Gem-SU treated mPSCs. Heatmaps show differentially expressed genes related to activation of purinergic signaling. Color codes indicate Z-scores of each condition (n=3 mice per group). B) Graph shows the quantification of the mean fluorescence intensity of IL-6 stainings described in ( pooled data of 3 biological replicates). C ) Graph shows the quantification of the mean fluorescence intensity of IL-6 stainings described in (pooled data of 3 biological replicates). D ) Immunoblots of human PSC cells treated for 15 min with supernatants of vehicle (Control-SU) or doxorubicin treated (Dox-SU) MIA PaCa-2 cells. Where indicated the medium was supplemented with A438079 (n = 3 biological replicates). E) IL-6 immunostaining of hPSCs treated with Control- or Dox-SU in the absence or presence of PPADS or A430879 (scale bar = 100 µm, n= 3 biological replicates). Graph shows the quantification of the IL-6-immunofluorescence. F) RT–qPCR analysis of the indicated genes in mPSCs treated for 24h with Control-SU or Gem-SU in the absence or presence of the P2X7-inhibtitor A430879 (n = 2 biological replicates). All data are mean ± s.d. and were analyzed by one-way ANOVA with Tukey’s multiple comparison test (*p≤0.05; **p≤0.01; ***p≤0.0005; **** p≤0.0001; ns = not significant).

Article Snippet: For RT-qPCR analysis, PSCs were treated for 24 hrs with Control-, Gem- or Dox-SU for immunoblot and immunofluorescence analysis cells were treated for 30 min. Where indicated, supernatants were supplemented with the pharmacological inhibitors rapamycin (10 μM; LC Laboratories, R5000), UO126 (10 μM; LC Laboratories, U6770), PPADS tetrasodium salt (60 μM; Santa Cruz Biotechnology, SC-253332), A438079 hydrochlorides (40 μM, Santa Cruz Biotechnology, SC-203788B) or BAY-1797 (2 μM, Hycultec, HY-130605).

Techniques: RNA Sequencing, Control, Activation Assay, Fluorescence, Western Blot, Immunostaining, Immunofluorescence, Quantitative RT-PCR, Comparison